46 results
6-K
EX-99.1
IFRX
InflaRx N.V.
5 Jun 24
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5:07pm
Exhibit 99.1
InflaRx Hosts R&D Event Highlighting the Promise of INF904
Thought leaders in complement inhibition, chronic spontaneous urticaria … -inflammatory therapeutics by targeting the complement system, today hosted a virtual R&D event focused on the company's oral small molecule C5aR inhibitor
6-K
EX-99.2
IFRX
InflaRx N.V.
5 Jun 24
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5:07pm
Exhibit 99.2
InflaRx - virtual R&D event INF904: oral C5aR inhibitor with best-in-class potential in the immuno-dermatology and broader I&I space
6-K
IFRX
InflaRx N.V.
5 Jun 24
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5:07pm
”) issued a press release titled, “InflaRx Hosts R&D Event Highlighting the Promise of INF904.” In connection with such announcement, on June 5, 2024 … , the Company hosted a virtual R&D event and presented its corporate presentation on immuno-dermatology where the Company provided details and developments
6-K
EX-99.2
IFRX
InflaRx N.V.
8 May 24
Report of Foreign Private Issuer
8:43am
to higher R&D expenses in the first three month of 2023 for the completion of the development activities for vilobelimab for the treatment of critically
6-K
EX-99.3
IFRX
InflaRx N.V.
8 May 24
Report of Foreign Private Issuer
8:43am
Exhibit 99.3
InflaRx Reports First Quarter 2024
Financial Results and Provides Business Update
Virtual R&D event to be held on June 5, 2024 from 12 … , and the additional potential of our drug candidates in the broader immunology inflammation field, we are excited about the path ahead of us”
Virtual R&D event
6-K
EX-99.1
gjoh7oxz2d 2ufd
21 Mar 24
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
7:05am
6-K
EX-99.2
sgr4wkku
4 Jan 24
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
4:16pm
6-K
EX-99.1
z37f4 yhv11i2g66
1 Nov 23
Current report (foreign)
8:04am
6-K
EX-99.1
gphk72
10 Aug 23
Report of Foreign Private Issuer
8:00am
6-K
EX-99.1
43kcg 7xsm03xt3mze9g
11 May 23
Current report (foreign)
8:00am
6-K
EX-99.4
7imp2 nsan3dyb52jw
9 Nov 22
Current report (foreign)
7:52am
6-K
EX-99.1
rdpwdt2
9 Nov 22
Current report (foreign)
7:52am
6-K
EX-99.3
4dqors7dh062y
5 Aug 22
Current report (foreign)
6:07am
6-K
EX-99.1
aspo6w1437a0qragx
5 Aug 22
Current report (foreign)
6:07am
6-K
EX-99.1
px4c0 6kzj5v
12 May 22
Current report (foreign)
8:30am
6-K
EX-99.1
oex375 c7
24 Mar 22
InflaRx Reports Full Year 2021 Financial and Operating Results
8:40am
6-K
cx4t368e46hf0h
3 Feb 22
Current report (foreign)
4:01pm
6-K
EX-99.2
1b2lnqjk
10 Jan 22
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
7:30am